Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copper Balance Study of ALXN1840 in Healthy Volunteers
NCT04594252Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change From Baseline in Mean Daily Copper Balance. Started Jul 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04594252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594252.